Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo.
Regulatory submissions planned in the United States and Europe in the first half of 2019.
These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network).
Beware of fraudulent and misleading emails being sent by unauthorized persons for job interviews/offers at Celgene Corporation. These messages are being sent to cheat individuals. Celgene never requires any payment to be made by any candidate to Celgene or to any individual or agency as part of our recruitment process. Celgene will never ask for bank account or credit card information pre-hire. Please report any such activity to Frank Marrero.